Filing Analysis
Corbus Pharmaceuticals announced updated Phase 1/2 clinical data for CRB-701, a Nectin-4 targeted antibody drug conjugate (ADC) for treating oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer, to be presented at the 2026 ASCO Annual Meeting.
📋 Key Facts
- Phase 1/2 study total safety population: 317 patients.
- In OPSCC (3.6 mg/kg dose), the confirmed objective response rate (cORR) was 42.9% (9/21) with a Disease Control Rate (DCR) of 85.7%.
- In cervical cancer (3.6 mg/kg dose), the cORR was 34.4% (11/32) with a DCR of 75.0%.
- Treatment discontinuations related to CRB-701 were low at 2.8%.
- The company is on track to initiate a registrational study in 2L OPSCC ('TEMPO-1') in summer 2026, with a randomized controlled study (n=250) design aligned with the FDA.
- Broad alignment reached with FDA on trial design for 2L cervical cancer study.
- Data cut date: April 1, 2026.
Corbus Pharmaceuticals entered into a two-year employment agreement with Nishant Saxena as Chief Business Officer, effective May 21, 2026. The company also announced initial equity grants for newly appointed board member Brent Pfeiffenberger and scheduled a conference call to discuss Phase 1/2 clinical data for CRB-701.
📋 Key Facts
- Entered into a 2-year employment agreement with Nishant Saxena as Chief Business Officer starting May 21, 2026.
- Mr. Saxena will receive an annual base salary of $470,000, a target bonus of up to 40%, 192,300 stock options, and 58,300 RSUs.
- Brent Pfeiffenberger received initial board equity awards of 24,700 stock options and 7,500 RSUs on May 19, 2026.
- Scheduled a conference call and webcast for May 26, 2026, to discuss clinical data from the Phase 1/2 study of CRB-701.
Corbus Pharmaceuticals announced the appointment of Brent Pfeiffenberger to its Board of Directors and received stockholder approval to increase its equity compensation plan by 3,000,000 shares. The filing also details the results of the 2026 Annual Meeting, including director elections and auditor ratification.
📋 Key Facts
- Brent Pfeiffenberger, CEO of Century Therapeutics and former BMS executive, was appointed to the Board on May 13, 2026.
- Stockholders approved an amendment to the 2024 Equity Compensation Plan, increasing authorized shares from 2,000,000 to 5,000,000.
- EisnerAmper LLP was ratified as the independent auditor for the fiscal year ending December 31, 2026.
- The Board was expanded to seven members following the appointment of Dr. Pfeiffenberger.
- Executive compensation and the frequency of future advisory votes (annually) were approved by stockholders.
Corbus Pharmaceuticals reported its financial results and operating metrics for the first fiscal quarter ended March 31, 2026. The filing includes a press release discussing the company's current financial condition and business outlook.
📋 Key Facts
- Disclosed financial results for the fiscal quarter ended March 31, 2026
- Press release issued and furnished on May 12, 2026
- Information provided under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure)
- Report signed by CEO Yuval Cohen
Corbus Pharmaceuticals updated the employment agreements for its CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026. The new two-year agreements establish updated base salaries, bonus targets, and severance provisions, including enhanced benefits in the event of a change in control.
📋 Key Facts
- CEO Yuval Cohen's base salary is set at $673,625 with a target annual bonus of 60%.
- CFO Sean Moran's base salary is set at $501,273 with a target annual bonus of 40%.
- Both agreements have a two-year term expiring on April 15, 2028.
- In a Change in Control Period, the CEO is entitled to 24 months of base salary and 2x target bonus severance.
- In a Change in Control Period, the CFO is entitled to 18 months of base salary and 1x target bonus severance.
- Severance for termination without cause outside of a change in control is set at 12 months of base salary for both officers.
Corbus Pharmaceuticals announced the completion of enrollment for its CANYON-1 Phase 1b clinical trial evaluating CRB-913 for the treatment of obesity. The trial is a 16-week study involving 240 participants, with results expected following study completion in the summer of 2026.
📋 Key Facts
- Last Patient First Visit (LPFV) achieved for CANYON-1 Phase 1b trial on April 14, 2026.
- CRB-913 is a once-daily oral CB1 inverse agonist targeting obesity.
- The study includes 240 obese, non-diabetic participants across three dose cohorts (20mg, 40mg, 60mg).
- Study completion is projected for the summer of 2026.
- Participants are dosed for 3 months with a 1-month follow-up period.
Corbus Pharmaceuticals announced the resignation of Chief Medical Officer Dominic Smethurst while simultaneously reporting broad alignment with the FDA on the registrational path for its ADC candidate, CRB-701. The company plans to initiate randomized controlled studies in HNSCC and cervical cancer to support potential accelerated approval.
🚩 Red Flags
- Resignation of the Chief Medical Officer (Dominic Smethurst) occurs just as the company transition into critical registrational clinical trials.
📋 Key Facts
- Chief Medical Officer Dominic Smethurst resigned on April 1, 2026, with an effective date of June 30, 2026.
- The company reached alignment with the FDA on the registration path for CRB-701, a Nectin-4 targeting antibody drug conjugate (ADC).
- Registrational studies will target second-line head and neck squamous cell carcinoma (HNSCC) and cervical cancer.
- The agreed-upon study designs utilize Objective Response Rate (ORR) as the primary endpoint for potential accelerated approval.
- Full approval for CRB-701 will be contingent on demonstrating Overall Survival (OS) benefit.
- The cervical cancer study will compare CRB-701 against physician's choice of chemotherapy or Tivdak.
Corbus Pharmaceuticals Holdings, Inc. announced its fiscal year 2025 financial results and provided a business outlook on March 9, 2026. The filing also includes an updated investor presentation used by management to describe the company's business operations.
📋 Key Facts
- Disclosed financial information and operating metrics for the fiscal year ended December 31, 2025
- Issued a press release on March 9, 2026, regarding business outlook
- Updated management's investor presentation (Exhibit 99.2)
- Information was furnished under Items 2.02 and 7.01, not deemed 'filed' for Section 18 purposes
Corbus Pharmaceuticals Holdings, Inc. furnished an updated investor presentation to be used by management for describing the company's business operations and strategy.
📋 Key Facts
- The filing was made on February 25, 2026, under Item 7.01 Regulation FD Disclosure.
- An updated investor presentation was included as Exhibit 99.1.
- The information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The report was signed by CEO Yuval Cohen.